IGHV3-13 as A Potential Drug Target for Neurodegenerative Diseases

Target Name: IGHV3-13

NCBI ID: G28449

IGHV3-13

Other Name(s): IGHV313 | immunoglobulin heavy variable 3-13 | Immunoglobulin heavy variable 3-13

IGHV3-13 as A Potential Drug Target for Neurodegenerative Diseases

IGHV3-13 (IGHV313) is a protein that is expressed in most tissues of the human body. It is a member of the intergenital nucleic acid (IGHN) family, which includes several proteins that play important roles in the development and maintenance of tissues during embryonic development. One of the unique features of IGHV3-13 is its ability to interact with the RNA polymerase II (RNA-II), which is a critical enzyme that participates in the gene expression process.

The IGHN family of proteins has been identified as potential drug targets due to their involvement in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. IGHV3-13 is particularly interesting as a drug target due to its role in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

IGHV3-13 has also been shown to play a role in the development of neurodegenerative diseases by promoting the production of toxic RNA species that can cause damage to nerve cells. IGHV3-13 has also been shown to interact with the RNA-II complex, which is responsible for transcribing the genetic information in the DNA into RNA. This interaction between IGHV3-13 and RNA-II suggests that IGHV3-13 may be a useful biomarker or drug target for the treatment of neurodegenerative diseases.

One of the potential benefits of targeting IGHV3-13 is its potential to bead-on-bead effect, which allows for the targeted delivery of small molecules to specific cellular compartments. This may be useful for the treatment of neurodegenerative diseases where damage to neural circuits is thought to be caused by the accumulation of misfolded or toxic RNA species.

Another potential benefit of targeting IGHV3-13 is its potential to modulate the levels of RNA-II in the brain. IGHV3-13 has been shown to interact with RNA-II and has been shown to modulate the levels of RNA-II in the brain. . This suggests that IGHV3-13 may be a useful drug target for the treatment of neurodegenerative diseases associated with elevated levels of RNA-II.

In conclusion, IGHV3-13 is a protein that has been shown to play a role in the development and progression of neurodegenerative diseases. Its interaction with the RNA-II complex and its potential to modulate the levels of RNA-II in the brain make it an attractive drug target for the treatment of these diseases. Further research is needed to determine the exact mechanisms by which IGHV3-13 promotes neurodegenerative diseases and to develop effective treatments.

Protein Name: Immunoglobulin Heavy Variable 3-13

Functions: V region of the variable domain of immunoglobulin heavy chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170)

The "IGHV3-13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGHV3-13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets